Moxifloxacin-containing triple therapy as second-line treatment for helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate

Helicobacter

Volumn 14, Issue 5, 2009, Pages 429-437

  Yoon, Hyuk ^b   Kim, Nayoung ^a,b   Lee, Byoung Hwan ^a   Hwang, Tae Jun ^a   Lee, Dong Ho ^a,b   Park, Young Soo ^a,b   Nam, Ryoung Hee ^a   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Eradication; H. pylori; Moxifloxacin; Resistance; Second line

Indexed keywords

AMOXICILLIN; ESOMEPRAZOLE; MOXIFLOXACIN; PROTON PUMP INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGAR DILUTION; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PATIENT COMPLIANCE; PERSISTENT INFECTION; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; STOMACH MUCOSA; STOMACH ULCER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA BREATH TEST; VOMITING;

HELICOBACTER PYLORI;

EID: 70349159147     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00709.x     Document Type: Article

References (42)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002 347 : 1175 1186.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
3. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 1825.
4. Kim JM, Kim JS, Jung HC, et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004 48 : 4843 4847.
5. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006 40 : 683 687.
6. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003 18 : 791 797.
7. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008 14 : 5385 5402.
8. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
9. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005 37 : 821 825.
10. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 421 427.
11. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006 48 : 19 24.
12. Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006 47 : 30 6.
13. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005 21 : 1241 1247.
14. Bago P, Vcev A, Tomic M, et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007 119 : 372 378.
15. Bago J, Pevec B, Tomic M, et al. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009 121 : 47 52.
16. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006 11 : 46 51.
17. Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007 12 : 623 628.
18. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 496.
19. Kim JM, Kim JS, Kim N, et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005 56 : 965 967.
20. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 603 609. (Pubitemid 30240753)
21. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003 17 (Suppl. B 36B 40B.
22. Paoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006 11 : 562 568.
23. Filipec Kanizaj T, Katicic M, Skurla B, et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009 14 : 29 35.
24. Gisbert JP, Pajares JM. Review article: Helicobacter pylori" rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 1057.
25. Di Caro S, Franceschi F, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009 41 : 480 485.
26. Sezgin O, Altintas E, Ucbilek E, et al. Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population. Helicobacter 2007 12 : 518 522.
27. Kilic ZM, Koksal AS, Cakal B, et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 2008 53 : 3133 3137.
28. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007 26 : 343 357.
29. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, et al. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006 28 : 1960 1966.
30. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007 44 : e5 8.
31. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009 14 : 61 5.
32. Moore RA, Beckthold B, Wong S, et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995 39 : 107 111.
33. Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999 4 : 106 112.
34. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004 26 : 940 950.
35. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007 56 : 475 479.
36. Uygun A, Kadayifci A, Safali M, et al. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007 8 : 211 215.
37. Michopoulos S, Tsibouris P, Bouzakis H, et al. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000 14 : 737 744.
38. Thong-Ngam D, Mahachai V. 14-Day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand. J Med Assoc Thai 2006 89 (Suppl. 3 S119 25.
39. Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000 14 : 745 750.
40. Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008 23 (Suppl. 2 S171 4.
41. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996 40 : 477 480.
42. Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 2004 42 : 4512 4518.